View in EDS HTML Full Text PDF Full Text

Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.

Saved in:
Bibliographic Details
Title: Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Authors: Toksvang LN; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Linea.natalie.toksvang@regionh.dk., Als-Nielsen B; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark., Bacon C; St. James Hospital, Dublin, Ireland., Bertasiute R; Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania., Duarte X; Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Pediatria, Lisbon, Portugal., Escherich G; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Helgadottir EA; Landspitali University Hospital, Reykjavik, Iceland., Johannsdottir IR; Oslo University Hospital, Oslo, Norway., Jónsson ÓG; Landspitali University Hospital, Reykjavik, Iceland., Kozlowski P; Örebro University Hospital, Örebro, Sweden., Langenskjöld C; Drottning Silvias Barnsjukhus, Gothenburg, Sweden., Lepik K; Tallinn Children's Hospital, Tallinn, Estonia., Niinimäki R; Oulu University Hospital and PEDEGRO Research Unit, University of Oulu, Oulu, Finland., Overgaard UM; Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Punab M; Tartu University Hospital, Tartu, Estonia., Räty R; Helsinki University Central Hospital, Helsinki, Finland., Segers H; Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium., van der Sluis I; Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Smith OP; Our Lady's Children Hospital, Dublin, Ireland., Strullu M; Université de Paris, hôpital universitaire Robert-Debré (APHP), Paris, France., Vaitkevičienė G; Center for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania., Wik HS; Oslo University Hospital, Oslo, Norway., Heyman M; Karolinska Institutet, Stockholm, Sweden.; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden., Schmiegelow K; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.; University of Copenhagen, Copenhagen, Denmark.
Source: BMC cancer [BMC Cancer] 2022 May 02; Vol. 22 (1), pp. 483. Date of Electronic Publication: 2022 May 02.
Publication Type: Clinical Trial Protocol; Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35501736
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Toksvang+LN%22">Toksvang LN</searchLink>; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Linea.natalie.toksvang@regionh.dk.<br /><searchLink fieldCode="AU" term="%22Als-Nielsen+B%22">Als-Nielsen B</searchLink>; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Bacon+C%22">Bacon C</searchLink>; St. James Hospital, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Bertasiute+R%22">Bertasiute R</searchLink>; Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.<br /><searchLink fieldCode="AU" term="%22Duarte+X%22">Duarte X</searchLink>; Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Pediatria, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Escherich+G%22">Escherich G</searchLink>; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Helgadottir+EA%22">Helgadottir EA</searchLink>; Landspitali University Hospital, Reykjavik, Iceland.<br /><searchLink fieldCode="AU" term="%22Johannsdottir+IR%22">Johannsdottir IR</searchLink>; Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Jónsson+ÓG%22">Jónsson ÓG</searchLink>; Landspitali University Hospital, Reykjavik, Iceland.<br /><searchLink fieldCode="AU" term="%22Kozlowski+P%22">Kozlowski P</searchLink>; Örebro University Hospital, Örebro, Sweden.<br /><searchLink fieldCode="AU" term="%22Langenskjöld+C%22">Langenskjöld C</searchLink>; Drottning Silvias Barnsjukhus, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Lepik+K%22">Lepik K</searchLink>; Tallinn Children's Hospital, Tallinn, Estonia.<br /><searchLink fieldCode="AU" term="%22Niinimäki+R%22">Niinimäki R</searchLink>; Oulu University Hospital and PEDEGRO Research Unit, University of Oulu, Oulu, Finland.<br /><searchLink fieldCode="AU" term="%22Overgaard+UM%22">Overgaard UM</searchLink>; Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Punab+M%22">Punab M</searchLink>; Tartu University Hospital, Tartu, Estonia.<br /><searchLink fieldCode="AU" term="%22Räty+R%22">Räty R</searchLink>; Helsinki University Central Hospital, Helsinki, Finland.<br /><searchLink fieldCode="AU" term="%22Segers+H%22">Segers H</searchLink>; Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22van+der+Sluis+I%22">van der Sluis I</searchLink>; Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Smith+OP%22">Smith OP</searchLink>; Our Lady's Children Hospital, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Strullu+M%22">Strullu M</searchLink>; Université de Paris, hôpital universitaire Robert-Debré (APHP), Paris, France.<br /><searchLink fieldCode="AU" term="%22Vaitkevičienė+G%22">Vaitkevičienė G</searchLink>; Center for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania.<br /><searchLink fieldCode="AU" term="%22Wik+HS%22">Wik HS</searchLink>; Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Heyman+M%22">Heyman M</searchLink>; Karolinska Institutet, Stockholm, Sweden.; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Schmiegelow+K%22">Schmiegelow K</searchLink>; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.; University of Copenhagen, Copenhagen, Denmark.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100967800%22">BMC cancer</searchLink> [BMC Cancer] 2022 May 02; Vol. 22 (1), pp. 483. <i>Date of Electronic Publication: </i>2022 May 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial Protocol; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100967800 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2407 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712407%22">14712407 </searchLink><i>NLM ISO Abbreviation: </i>BMC Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35501736
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12885-022-09522-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 483
    Titles:
      – TitleFull: Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Toksvang LN
      – PersonEntity:
          Name:
            NameFull: Als-Nielsen B
      – PersonEntity:
          Name:
            NameFull: Bacon C
      – PersonEntity:
          Name:
            NameFull: Bertasiute R
      – PersonEntity:
          Name:
            NameFull: Duarte X
      – PersonEntity:
          Name:
            NameFull: Escherich G
      – PersonEntity:
          Name:
            NameFull: Helgadottir EA
      – PersonEntity:
          Name:
            NameFull: Johannsdottir IR
      – PersonEntity:
          Name:
            NameFull: Jónsson ÓG
      – PersonEntity:
          Name:
            NameFull: Kozlowski P
      – PersonEntity:
          Name:
            NameFull: Langenskjöld C
      – PersonEntity:
          Name:
            NameFull: Lepik K
      – PersonEntity:
          Name:
            NameFull: Niinimäki R
      – PersonEntity:
          Name:
            NameFull: Overgaard UM
      – PersonEntity:
          Name:
            NameFull: Punab M
      – PersonEntity:
          Name:
            NameFull: Räty R
      – PersonEntity:
          Name:
            NameFull: Segers H
      – PersonEntity:
          Name:
            NameFull: van der Sluis I
      – PersonEntity:
          Name:
            NameFull: Smith OP
      – PersonEntity:
          Name:
            NameFull: Strullu M
      – PersonEntity:
          Name:
            NameFull: Vaitkevičienė G
      – PersonEntity:
          Name:
            NameFull: Wik HS
      – PersonEntity:
          Name:
            NameFull: Heyman M
      – PersonEntity:
          Name:
            NameFull: Schmiegelow K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: 2022 May 02
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1471-2407
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC cancer
              Type: main
ResultId 1